Schrodinger, Inc.
Business
Schrödinger transforms drug discovery and materials science by providing physics-based computational software that predicts molecular properties more rapidly and at lower cost than traditional methods. The company licenses its platform to biopharmaceutical companies, academic institutions, and industrial organizations worldwide, and generates software revenue from annual licenses. Schrödinger operates two main businesses: a software division serving the top 20 pharmaceutical companies and materials science customers, and a drug discovery division pursuing collaborative programs with biopharmaceutical partners and advancing proprietary clinical-stage candidates including SGR-1505 (MALT1 inhibitor) and SGR-3515 (Wee1/Myt1 inhibitor) through Phase 1 trials.
Summary from 10-K filed 2026-02-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 256 | 208 | 217 | 181 | 138 | |
| Total cost of revenues | 113 | 75 | 76 | 80 | 72 | |
| Gross profit | 143 | 132 | 141 | 101 | 66 | |
| Research and development | 173 | 202 | 182 | 126 | 91 | |
| Sales and marketing | 41 | 40 | 37 | 31 | 22 | |
| General and administrative | 95 | 100 | 99 | 91 | 64 | |
| Total operating expenses | 310 | 341 | 318 | 248 | 177 | |
| Loss from operations | −167 | −209 | −177 | −147 | −111 | |
| Gain on equity investments | 0 | 0 | 147 | 12 | −2 | |
| Change in fair value of equity investments | 48 | 6 | 53 | −18 | 11 | |
| Other income | 16 | 18 | 20 | 4 | 1 | |
| Total other income | 65 | 24 | 220 | −2 | 11 | |
| (Loss) income before income taxes | −102 | −186 | 43 | −149 | −101 | |
| Income tax expense | 939,000 | 1 | 2 | 63,000 | 411,000 | |
| Net (loss) income | −103 | −187 | 41 | −149 | −100 | |
| Net (loss) income per share attributable to common and limited common stockholders, basic (in USD per share) | −1.41 | −2.57 | 0.57 | −2.1 | −1.42 | |
| Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares) | 73 | 73 | 72 | 71 | 71 | |
| Net (loss) income per share of common and limited common stockholders, diluted (in USD per share) | −1.41 | −2.57 | 0.54 | −2.1 | −1.42 | |
| Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares) | 73 | 73 | 75 | 71 | 71 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 231 | 147 | 155 | 90 | 120 | |
| Restricted cash | 7 | 15 | 6 | 5 | 3 | |
| Marketable securities | 165 | 205 | 308 | 361 | 456 | |
| Accounts receivable, net of allowance for doubtful accounts of $440 and $210 | 83 | 236 | 66 | 56 | 32 | |
| Unbilled and other receivables, net of allowance for unbilled receivables of $140 and $100 | 21 | 20 | 23 | 13 | 9 | |
| Prepaid expenses | 13 | 12 | 10 | 9 | 5 | |
| Total current assets | 519 | 635 | 568 | 534 | 625 | |
| Property and equipment, net | 19 | 24 | 23 | 14 | — | |
| Equity investments | 74 | 43 | 83 | 26 | 43 | |
| Goodwill | 5 | 5 | 5 | 5 | 0 | |
| Right of use assets - operating leases | 103 | 112 | 118 | 106 | 75 | |
| Other assets | 6 | 4 | 6 | 3 | 3 | |
| Total assets | 726 | 823 | 803 | 689 | 756 | |
| Accounts payable | 11 | 11 | 17 | 9 | 8 | |
| Accrued payroll, taxes, and benefits | 39 | 42 | 32 | 25 | 18 | |
| Deferred revenue | 113 | 112 | 56 | 58 | 55 | |
| Lease liabilities - operating leases | 16 | 17 | 17 | 11 | 2 | |
| Other accrued liabilities | 9 | 10 | 12 | 6 | 7 | |
| Total current liabilities | 189 | 192 | 134 | 109 | 91 | |
| Deferred revenue, long-term | 79 | 109 | 9 | 26 | 30 | |
| Lease liabilities - operating leases, long-term | 93 | 101 | 111 | 105 | 78 | |
| Other liabilities, long-term | 1 | 146,000 | 667,000 | 800,000 | 300,000 | |
| Total liabilities | 362 | 402 | 254 | 241 | 199 | |
| Commitments and contingencies (Note 6) | — | — | — | — | — | |
| Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | 0 | 0 | |
| Additional paid-in capital | 992 | 946 | 886 | 829 | 787 | |
| Accumulated deficit | −629 | −526 | −338 | −379 | −230 | |
| Accumulated other comprehensive income | 107,000 | 220,000 | 281,000 | −2 | −651,000 | |
| Total stockholders' equity | 364 | 421 | 549 | 448 | 557 | |
| Total liabilities and stockholders' equity | 726 | 823 | 803 | 689 | 756 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Changes in fair value of equity investments | −48 | −6 | −53 | 18 | −11 | |
| Depreciation and amortization | 6 | 6 | 6 | 4 | 3 | |
| Stock-based compensation | 43 | 50 | 48 | 40 | 26 | |
| Noncash investment accretion | −2 | −8 | −8 | 629,000 | 5 | |
| Loss on disposal of property and equipment | 20,000 | 8,000 | 142,000 | 19,000 | 140,000 | |
| Accounts receivable, net | 153 | −170 | −10 | −24 | −321,000 | |
| Unbilled and other receivables | −2 | 3 | −10 | −4 | −5 | |
| Reduction in the carrying amount of right of use assets - operating leases | 9 | 9 | 8 | 7 | 6 | |
| Prepaid expenses and other assets | −2 | −3 | −8 | −7 | −1 | |
| Accounts payable | 908,000 | −6 | 7 | 1 | −411,000 | |
| Accrued payroll, taxes, and benefits | −3 | 10 | 7 | 6 | 6 | |
| Deferred revenue | −29 | 155 | −18 | −2 | −1 | |
| Lease liabilities - operating leases | −9 | −10 | −4 | 2 | −3 | |
| Other accrued liabilities | 91,000 | −2 | 6 | −1 | 3 | |
| Net cash provided by (used in) operating activities | 14 | −157 | −137 | −120 | −71 | |
| Purchases of property and equipment | −1 | −7 | −13 | −8 | −7 | |
| Purchases of equity investments | 0 | −3 | −4 | −600,000 | −4 | |
| Distribution from equity investment | 0 | 0 | 147 | 12 | 375,000 | |
| Proceeds from sale and disposition of equity investments | 18 | 49 | 0 | 0 | 16 | |
| Purchases of marketable securities | −313 | −251 | −321 | −271 | −415 | |
| Proceeds from maturity of marketable securities | 355 | 362 | 384 | 365 | 393 | |
| Net cash provided by investing activities | 58 | 149 | 193 | 90 | −17 | |
| Proceeds from issuances of common stock upon stock option exercises | 3 | 1 | 9 | 2 | — | |
| Proceeds from issuance of common stock in ATM offering | 0 | 9 | 0 | 0 | — | |
| Payment of offering costs | 0 | −177,000 | −373,000 | 0 | 0 | |
| Principal payments on finance leases | −58,000 | −58,000 | −19,000 | 0 | 0 | |
| Net cash provided by financing activities | 3 | 10 | 9 | 2 | 8 | |
| Net increase in cash and cash equivalents and restricted cash | 75 | 2 | 65 | −28 | −80 | |
| Purchases of property and equipment in accounts payable | 40,000 | 162,000 | 192,000 | 169,000 | 705,000 | |
| Purchases of property and equipment in accrued liabilities | 81,000 | 157,000 | 457,000 | 293,000 | 0 | |
| Acquisition of right of use assets - operating leases, contingency resolution | 0 | 3 | 514,000 | 2 | 0 | |
| Acquisition of right of use assets in exchange for lease liabilities - operating leases | 0 | 0 | 15 | 35 | 71 | |
| Acquisition of right of use assets in exchange for lease liabilities - finance leases | 0 | 0 | 279,000 | 0 | 71 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Schrodinger, Inc.'s CIK number?
Schrodinger, Inc.'s SEC CIK number is 0001490978 (1490978). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Schrodinger, Inc.'s SEC filings?
All of Schrodinger, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Schrodinger, Inc. last report earnings?
Schrodinger, Inc. (SDGR) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001490978-26-000036). This is Schrodinger, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Schrodinger, Inc.'s most recent earnings 8-K?
Schrodinger, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001490978-26-000036. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Schrodinger, Inc.'s latest earnings 8-K →
Look up any company's CIK number →